Medicine (Northern Health) - Theses

Permanent URI for this collection

Search Results

Now showing 1 - 5 of 5
  • Item
    Thumbnail Image
    Peri-Operative Myocardial Injury and Type 2 Myocardial Infarction
    Rafiudeen, Rifly ( 2023-04)
    This thesis explores the major themes of Peri-Operative Myocardial Infarction and Injury (PMI), and Type 2 Myocardial Infarction (T2MI), both entities where understanding of pathophysiological mechanisms and clinical presentation and management are not completely understood and continuing to evolve (1, 2). PMI could be either T2MI, Type 1 Myocardial Infarction (T1MI), or Myocardial Injury, where T1MI refers to an acute plaque rupture and thrombus formation. T2MI on the other hand refers to an oxygen supply-demand mismatch to the myocardium, precipitated by a variety of potential factors, with or without underlying stable coronary plaque (3). Both PMI and T2MI are commonly encountered in a hospital in-patient setting, following non-cardiac surgery and precipitant other medical conditions respectively (4-6). Pivotal to the diagnosis of both is the measurement of cardiac troponin, and the other major thread to this body of work is the impact that the relatively new high-sensitivity troponin assays have had to the landscape of these conditions clinically, and to our understanding of them pathophysiologically (7). There are currently no proven, specific interventions that reduce cardiovascular risk in patients undergoing non-cardiac surgery (8, 9). The incidence of PMI is substantial, in the order of 30% for all non-cardiac surgery (10-12). In this setting, there is a great need for specific interventions that can reduce this incidence in patients at risk - this is the basis for the world-first, prospective, double-blind randomised multicentre placebo-controlled trial that is part of this thesis, which investigates a first-in-class drug Ivabradine in preventing PMI in an elderly population undergoing orthopaedic surgery for acute fracture. T2MI accounts for the majority of troponin elevations in a hospital population, and has similar if not worse prognosis to T1MI (13-15). However, the diagnosis, investigation, and management of T2MI at the bedside in any given patient is not always clear. Determining the likely pathophysiological process based on clinical information alone in some cases may be difficult, and there is a thought that the newer high-sensitivity troponin assays may exacerbate this. The broad aims of this body of work are: 1. To better understand the pathophysiological mechanisms of PMI and T2MI, in particular the role of increased heart rate 2. To investigate an intervention with Ivabradine started pre-operatively to reduce the risk of PMI, in a setting where there are currently no proven therapies. 3. To evaluate determinants and risk factors for PMI and T2MI in specific clinical contexts, and investigate long-term outcomes after PMI. 4. To explore the effect of the new high sensitivity troponin assay on all of the above, in particular the clinical diagnosis and landscape of both PMI and T2MI. We achieved the above aims through the following methods: 1. A world-first, prospective, double-blind, randomised, multicentre placebo-controlled trial investigating a novel use of the first-in-class drug Ivabradine. 2. A world-first prospective case series using intra-coronary Optical Coherence Tomography (OCT) imaging in an inpatient T2MI population. 3. A large-scale retrospective analysis of an entire tertiary hospital’s experience in the transition to the new high sensitivity troponin assay from a standard assay, focused on all T2MI relative to all T1MI. REFERENCES 1. Mauermann E, Puelacher C, Lurati Buse G. Myocardial injury after noncardiac surgery: an underappreciated problem and current challenges. Current opinion in anaesthesiology. 2016;29(3):403-12. 2. Helwani MA, Amin A, Lavigne P, Rao S, Oesterreich S, Samaha E, et al. Etiology of Acute Coronary Syndrome after Noncardiac Surgery. Anesthesiology. 2018. 3. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;138(20):e618-e51. 4. Liem VGB, Hoeks SE, Grune F, Mol K, Wesdorp F, Stolker RJ, et al. Prognostic value of postoperative high-sensitivity troponin T in patients with different stages of kidney disease undergoing noncardiac surgery. British journal of anaesthesia. 2018;120(1):84-93. 5. Puelacher C, Lurati Buse G, Seeberger D, Sazgary L, Marbot S, Lampart A, et al. Perioperative Myocardial Injury After Noncardiac Surgery: Incidence, Mortality, and Characterization. Circulation. 2017. 6. Collinson P, Lindahl B. Type 2 myocardial infarction: the chimaera of cardiology? Heart (British Cardiac Society). 2015;101(21):1697-703. 7. Chong CP, van Gaal WJ, Savige J, Lim WK. Cardiac injury and troponin testing after orthopaedic surgery. Injury. 2011;42(9):855-63. 8. Hoshijima H, Denawa Y, Mihara T, Takeuchi R, Kuratani N, Mieda T, et al. Efficacy of prophylactic doses of intravenous nitroglycerin in preventing myocardial ischemia under general anesthesia: A systematic review and meta-analysis with trial sequential analysis. Journal of clinical anesthesia. 2017;40:16-22. 9. Devereaux PJ, Duceppe E, Guyatt G, Tandon V, Rodseth R, Biccard BM, et al. Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. Lancet (London, England). 2018;391(10137):2325-34. 10. Ollila A, Vikatmaa L, Virolainen J, Vikatmaa P, Leppaniemi A, Alback A, et al. Perioperative Myocardial Infarction in Non-Cardiac Surgery Patients: A Prospective Observational Study. Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society. 2017;106(2):180-6. 11. Toda H, Nakamura K, Nakagawa K, Watanabe A, Miyoshi T, Nishii N, et al. Diastolic Dysfunction Is a Risk of Perioperative Myocardial Injury Assessed by High-Sensitivity Cardiac Troponin T in Elderly Patients Undergoing Non-Cardiac Surgery. Circulation journal : official journal of the Japanese Circulation Society. 2018;82(3):775-82. 12. Bass AR, Szymonifka JD, Rondina MT, Bogardus M, Scott MG, Woller SC, et al. Postoperative Myocardial Injury and Inflammation Is Not Blunted by a Trial of Atorvastatin in Orthopedic Surgery Patients. HSS journal : the musculoskeletal journal of Hospital for Special Surgery. 2018;14(1):67-76. 13. Chapman AR, Adamson PD, Mills NL. Assessment and classification of patients with myocardial injury and infarction in clinical practice. Heart (British Cardiac Society). 2017;103(1):10-8. 14. Smilowitz NR, Naoulou B, Sedlis SP. Diagnosis and management of type II myocardial infarction: increased demand for a limited supply of evidence. Current atherosclerosis reports. 2015;17(2):478. 15. Sandoval Y, Smith SW, Thordsen SE, Apple FS. Supply/demand type 2 myocardial infarction: should we be paying more attention? Journal of the American College of Cardiology. 2014;63(20):2079-87.
  • Item
    Thumbnail Image
    Global coagulation assays as predictive biomarkers in thrombotic disease
    Wang, Jue ( 2023-08)
    Venous thromboembolism (VTE) continues to be a leading cause of morbidity and mortality globally. As was evident during the COVID-19 pandemic, thrombosis also exacerbates a number of inflammatory illnesses through the mechanism of ‘thrombo-inflammation’. Predicting thrombotic complications continues to be a major challenge in the management of VTE and other thrombo-inflammatory diseases. Though efforts have been made to find biomarkers that can enhance our capacity to risk-stratify thrombotic risk, none have yet been successfully adopted clinically. Better predictive biomarkers are required to personalise anticoagulant medication such that thrombotic consequences in high-risk persons are minimised and low-risk individuals are not exposed to unnecessary bleeding risk. In this thesis, we explore the use of global coagulation assays (GCAs), in particular the overall haemostatic potential (OHP) assay, modified by a lower concentration of thrombin trigger (0.003U/mL) as a predictive biomarker in VTE, post-thrombotic syndrome (PTS) and COVID-19. We reviewed our local experience using D-dimer as a predictive biomarker for VTE recurrence. Although high D-dimer was shown to be correlated with increased risk of VTE recurrence, there were important drawbacks including poor specificity, a high rate of VTE recurrence in individuals who test negative for D-dimer, and the requirement to test off anticoagulation. Next, we described variations of fibrin generation and fibrinolysis in health controls, as determined by the OHP assay. Age >50 years and female sex was associated with high fibrin generation capacity and lower fibrinolytic capacity. Current predictive biomarkers for VTE recurrence require testing after a period of anticoagulation withdrawal. We demonstrate that OHP assay retains predictive ability for VTE recurrence, even in the presence of therapeutic anticoagulation, and outperformed D-dimer. Similarly, high OHP>13 units during therapeutic anticoagulation was an independent predictor of progression to PTS (OR 2.17, 95%CI 1.06-4.43, p=0.03). This was incorporated into a multivariate prediction model for PTS, with a c-statistic of 0.77. Pulmonary microthrombi and abnormal fibrin deposition in the alveoli have been implicated in the pathogenesis of severe COVID-ARDS. Using residual plasma collected in 2022 Omicron patients at hospital admission, we found high OHP >20 units to be an independent predictor of oxygen requirement (OR 3.23, 95%CI 1.52-6.86, p=0.002). A multivariate prediction model incorporating OHP was constructed with excellent c-statistic of 0.86. Finally, we show that DOAC-stop can be used to remove the in-vitro interference of DOACs and allow thrombin generation assays to be performed even in anticoagulated individuals, meaning thrombin generation results can now be evaluated as a predictive biomarker without stopping anticoagulation. Overall, we have shown the OHP assay to be a comprehensive global coagulation assay with promising predictive potential in VTE, PTS and COVID-19. Future research may expand its application to other thrombo-inflammatory diseases and combine multiple global coagulation assays with other novel biomarkers, to better model the coagulation sequence and refine thrombotic risk stratification.
  • Item
    Thumbnail Image
    Global coagulation assays in health and disease
    Lim, Hui Yin ( 2022)
    Thrombosis is a major global cause of morbidity and mortality, and predicting the risk of thrombotic and cardiovascular complications remain a challenge in modern medicine. Clinical surrogate markers and conventional coagulation testing, which only measures the time to start of clot formation, do not sufficiently predict individual risks. Global coagulation assays (GCA), which includes the assessment of the final products of the coagulation cascade, namely thrombin and fibrin, may be helpful adjunctive tools. Whilst GCAs have been more widely investigated in bleeding states, their role in thrombotic disorders is less well-established. In this thesis, we investigated the use of GCAs such as thromboelastography (TEG), calibrated automated thrombogram (CAT) and overall haemostatic potential assay (OHP) in healthy controls and a variety of disease states. These included thrombocytopenia and hypercoagulable states such as diabetes mellitus, plasma cell dyscrasia, the influence of hormone status, particularly oestrogen (transgender women on oestradiol therapy) as well as in coronavirus (COVID-19). We described the effect of basic demographic characteristics in healthy controls, particularly age and gender, on GCAs. Female controls demonstrated more hypercoagulable TEG and CAT parameters while age appeared to influence TEG, but not CAT parameters. Interestingly, healthy controls with “flattened” thrombin curves were associated with worse cardiovascular risk profile, possibly attributable to increased TFPI, suggesting a degree of compensation within the coagulation system in response to endothelial activation. Despite the common association of thrombocytopenia with bleeding, quantitative platelet counts do not always accurately predict this risk and thrombosis can occur despite thrombocytopenia. We reported while markedly thrombocytopenic patients demonstrated hypocoagulable profiles, patients with mild thrombocytopenia paradoxically appeared to have more hypercoagulable parameters. Overall, GCAs demonstrated the ability to help clinicians further discriminate thrombocytopenic patients. There is significant heterogeneity in the incidence and severity of diabetes-associated vascular complications, with limitations to clinical surrogate risk factors and glycated haemoglobin (HbA1c) as risk stratifiers. In addition to diabetes being a hypercoagulable state, particularly on TEG and OHP, we found several parameters to be associated with increased risk of diabetic complications and proposed a prediction model using a combination of GCA parameters (C-statistic 0.82). This is of clinical and prognostic significance as it may have utility in detecting early vascular complications and provide an indicator for early intervention. A larger prospective study with long-term follow-up of patient outcomes is ongoing. Monoclonal gammopathy of unknown significance (MGUS) is considered the clinically asymptomatic precursor of multiple myeloma although both forms are associated with an increased thrombotic risk. Contrary to expectations, there were no significant differences in the GCA parameters between patients with multiple myeloma and its MGUS precursor. However, patients who had arterial thrombotic events during the follow-up period demonstrated hypofibrinolysis based upon the OHP parameters. In exploring the role of hormonal influences on GCAs, we found that transgender women on oestradiol therapy demonstrated hypercoagulable TEG and CAT parameters as well as increased fibrinolysis compared to cisgender males. There was no significant difference seen relative to cisgender females, reflecting the shift towards feminisation. The route of estradiol delivery, its duration of use or the presence of concurrent anti-androgen therapy did not influence the GCA parameters. It is now well established that COVID-19 patients are susceptible to coagulopathy and thrombotic complications. We demonstrated marked impairment of fibrinolysis in COVID-19 patients compared to healthy controls and septic patients. Furthermore, patients with markedly increased OHP were more likely to require intensive care admission and ventilatory support. This suggests fibrinolysis may be an important therapeutic target in the management of one of the most challenging conditions we have faced in a century. Overall, we have shown that GCA appear to provide an advantage over conventional coagulation assays in the assessment of haemostatic function. While there are still limitations impeding the general applicability of these assays, further technical improvements may facilitate their introduction into clinical practice. Our data also suggest that these assays may have clinical utility in refining the thrombotic risk stratification. Further larger prospective studies to validate these findings are warranted.
  • Item
    Thumbnail Image
    Non-Newtonian Blood Flow Simulation to Improve Detection of Coronary Atherosclerosis and its Complications
    Thondapu, Vikas Satyaram ( 2018)
    Disturbances in arterial blood flow and endothelial shear stress (ESS) are associated with pathological processes underlying atherosclerosis and complications after stent placement. Image-based computational fluid dynamic (CFD) simulations allow in vivo estimation of ESS and other indices of flow disturbances. While low ESS is a relatively sensitive marker of future plaque progression, it remains too non-specific for clinical application. Possible improvements include incorporation of more realistic simulation methodologies. Although there are many possible ways to improve or change simulation accuracy, such as the choice of imaging, reconstruction techniques, boundary conditions, incorporation of arterial wall compliance, the primary aim of this thesis was to evaluate the effect of non-Newtonian rheology on ESS calculation. Although blood is a non-Newtonian fluid, most CFD studies assume blood to be a Newtonian fluid with constant viscosity. As opposed to the Newtonian model, non-Newtonian rheological models treat blood viscosity as a variable solved during CFD simulation. As a result, the non-Newtonian assumption offers two hypothetical advantages over the Newtonian model: 1) improved accuracy in calculation of traditional haemodynamic indices; 2) novel viscosity-based indices of blood flow disturbances are made available, and which may correlate with atherosclerosis. These primary hypotheses are investigated in this thesis by using CFD in combination with high-resolution optical coherence tomographic (OCT) imaging of atherosclerotic plaques and stents in patients with coronary artery disease. This work began with a randomised controlled trial of 60 patients comparing two second-generation drug-eluting stents using OCT imaging immediately after implantation and at 6 months (Chapter 8). Although there were no significant differences in the primary endpoint of stent malapposition, the platinum-chromium stent demonstrated a significantly higher incidence of late longitudinal deformation without concurrent events during 12-month clinical follow up. Next, non-Newtonian CFD simulation was performed in 7 patients who received a fully bioabsorbable coronary scaffold and OCT imaging immediately after implantation and 5 years later (Chapter 9). Low ESS between scaffold struts after implantation significantly improved by 5 years, and the overall ESS distribution narrowed to more normal physiologic levels associated with vascular quiescence. Up to 10-fold increases in blood viscosity were identified near scaffold struts, but peak viscosity in the scaffolded segment significantly decreased by 5 years. Comparison of CFD results using Newtonian versus non-Newtonian rheological models was then undertaken in 16 patients who had non-culprit plaques completely imaged in baseline and 6-month OCT imaging. By purely quantitative comparison of rheological models, the Newtonian model significantly underestimates ESS, resulting in up to a 40% higher estimate of vessel areas exposed to atherogenic low ESS (Chapter 10). While the Newtonian and non-Newtonian models can lead to different conclusions about the relationship of ESS with underlying plaque composition, non-Newtonian indices local blood viscosity (LBV) and local Reynolds number (ReL) are significantly and independently associated with underlying calcium and lipid, respectively (Chapter 11). Further, vessel areas exposed to high ESS along with both high and low ReL demonstrate increases in lipid over 6 months, indicating the role of high inertial and viscous forces in lipid accumulation (Chapter 12). Finally, blood flow disturbances were evaluated in 18 patients with acute plaque erosion and thrombus (Chapter 13). High gradient of ESS and high ReL were significantly associated with the presence of thrombus, implying their role in acute coronary syndrome due to plaque erosion.
  • Item
    Thumbnail Image
    Health assets and deficits in hospitalised older adults
    Gregorevic, Katherine Jennifer ( 2019)
    Frailty is a loss of physiological reserve that leaves individuals at risk of poor recovery when exposed to a stressor. Frailty has been identified as a risk factor for poor outcomes for older adults when they are admitted to hospital, although there are still some barriers to implementation of measurement tools. Some frail older adults will still make a good recovery. Health assets are factors that are associated with health and recovery and are also desirable in their own right. Inclusion of health assets in models of illness and recovery may improve prognostication and identify patient centred strategies to facilitate recovery. Aims of the PhD 1. Determine whether is feasible to measure frailty based on routine clinical assessment 2. Examine whether health assets can be identified in hospitalised older adults 3. Investigate whether individual health assets improve outcomes for hospitalised older adults 4. Develop a health assets index 5. Validate the health assets index in hospitalised older adults Methods In addressing these aims, five phases of research were undertaken: Phase 1: A systematic review of the literature was undertaken to identify health assets in the hospital setting. MEDLINE, EMBASE, CINAHL and PsycINFO were searched to identify studies examining outcomes for hospitalised older adults. Included studies examined at least one potential individual health asset, which was a psychosocial characteristic or health characteristic. Study quality was assessed, and findings are narratively described. Phase 2: A prospective cohort study was conducted in an acute general medical unit to determine whether frailty could be measured based on routine clinical information by junior medical staff. All patients aged 65 and over admitted to a general medical unit during August and September 2013 were eligible for the study. CFS score at baseline was documented by a member of the treating medical team. Demographic information and outcomes were obtained from medical records. The primary outcomes were functional decline and death within three months. Phase 3: A secondary analysis of an existing data set was conducted to examine the interaction between health assets and frailty. Patients of 1418 aged ≥ 70 years admitted to 11 hospitals in Australia were evaluated at admission using the interRAI assessment system for Acute Care, which surveys a large number of domains, including cognition, communication, mood and behaviour, activities of daily living, continence, nutrition, skin condition, falls and medical diagnosis. The data set was interrogated for potential health assets and a multiple logistic regression adjusted for frailty index, age and gender as covariates was performed for the outcomes mortality, length of stay, readmission and new need for residential care. Phase 4: Based on phases 2 and 3, a heath assets index was created. A pilot study was conducted to determine the feasibility of collecting this information in hospitalised older adults. Phase 5: A prospective cohort study was conducted to determine whether the health assets index had predictive validity for older inpatients. Adults aged 70 and older with unplanned admission to hospital were eligible to participate. Frailty and other co-variates were measured. The primary outcomes were mortality at 30 days and functional decline at discharge. Results Phase 1: Nine prospective cohort and two retrospective cohort studies were identified. subjective, functional and biological health assets were identified. Health assets were associated with decreased risk of post-hospital mortality, functional decline, new need for residential care and readmission. Phase 2: Frailty was assessed in 95 % of 179 eligible patients. 45 % of patients experienced functional decline and 11 % died within three months. 40 % of patients were classified as vulnerable/mildly frail, and 41 % were moderately to severely frail. When patients in residential care were excluded, increasing frailty was associated with functional decline (p = 0.011). Increasing frailty was associated with increasing mortality within three months (p = 0.012). Phase 3: Inpatient mortality was 3% and 4.5% of patients died within 28 days of discharge. Median length of stay was 7 days (IQR 4-11). In multivariate analysis that includes frailty, being able to walk further [OR 0.08 (0.01-0.63)], ability to leave the house [OR 0.35 (0.17-0.74)] and living alone [OR 0.28 (0.10-0.79)] were protective against mortality. The presence of a support person was associated with a decreased length of stay [OR 0.14 (0.08-0.25)]. Phase 4: It was feasible to measure health assets in older adults admitted to hospital. The time taken of 2-3 minutes indicated that it was not too onerous. Some questions were adjusted to make the wording clearer to participants. Phase 5: There were 298 participants, with an average age of 84.7 and 66% were women. 80.1% had a frailty score of greater than 0.25, with a population mean score of 0.38 (SD 0.12). The mean HAI score was 10.86 (SD 2.87) with a minimum of 5.5 and a maximum of 15. 56.4% of participants had functional decline on discharge from hospital and there was 5.7% 30 day mortality. There was an inverse relationship between frailty and health assets. In a multivariate analysis that accounted for interaction, for those who were not frail, a higher number of health assets was associated with lower mortality. This relationship was reversed at higher levels of frailty. Conclusions It is possible to measure frailty using routine clinical information, but the time taken to enter data is likely to present an ongoing barrier to frailty measurement, which can be overcome with the use of an electronic medical record. Health assets can be identified in older adults who have been admitted to hospital. A higher number of health assets is associated with a decreased level of frailty. Health assets may confer protection against mortality in more robust older adults. Further research could help to elucidate strategies that older adults identify as important and how these can be applied in the hospital setting.